Company / Gross Margin
Phathom Pharmaceuticals, Inc. Gross Margin History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
87.1%
FY2025
5-year range
75.5% / 87.1%
FY2023-FY2025
Trend
+15.3%
vs FY2024
Sector context
#6 of 28
Health Care
What the data says
Phathom Pharmaceuticals, Inc.'s gross margin of 87.1% is higher than 79% of companies in the Health Care sector (FY2025). Improved from 75.5% to 87.1% over the past 2 years.
Based on SEC 10-K filings.
87.1% in FY2025. Top quartile in the Health Care sector.
Improved from 75.5% to 87.1% over the past 2 years.
Health Care sector context is included.
Gross Margin over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
Top 21% in Health CareTop 21% of 28This company 87.1% Sector average 60.3%
▼
+44.4% above sector average
Key checks
Key Insights
- In FY2025, gross margin increased 15.3% year-over-year.
- Currently 26.8pp above the Health Care sector average.
Company context
Key Data Points
- Altman Z-Score -6.09 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | 87.1% | +15.3% |
| FY2024 | 75.5% | +0.0% |
| FY2023 | 75.5% | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026